ES2351876T3 - Sitio de enlazamiento del ligando de rage y usos del mismo. - Google Patents

Sitio de enlazamiento del ligando de rage y usos del mismo. Download PDF

Info

Publication number
ES2351876T3
ES2351876T3 ES98952204T ES98952204T ES2351876T3 ES 2351876 T3 ES2351876 T3 ES 2351876T3 ES 98952204 T ES98952204 T ES 98952204T ES 98952204 T ES98952204 T ES 98952204T ES 2351876 T3 ES2351876 T3 ES 2351876T3
Authority
ES
Spain
Prior art keywords
peptide
cell
srage
antibody
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98952204T
Other languages
English (en)
Spanish (es)
Inventor
Shi Du Yan
Ira Lamster
David Stern
Ann Marie Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Application granted granted Critical
Publication of ES2351876T3 publication Critical patent/ES2351876T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
ES98952204T 1997-10-09 1998-10-09 Sitio de enlazamiento del ligando de rage y usos del mismo. Expired - Lifetime ES2351876T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/948,131 US6555651B2 (en) 1997-10-09 1997-10-09 Ligand binding site of rage and uses thereof
US948131 1997-10-09

Publications (1)

Publication Number Publication Date
ES2351876T3 true ES2351876T3 (es) 2011-02-11

Family

ID=25487337

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98952204T Expired - Lifetime ES2351876T3 (es) 1997-10-09 1998-10-09 Sitio de enlazamiento del ligando de rage y usos del mismo.

Country Status (11)

Country Link
US (1) US6555651B2 (enExample)
EP (2) EP2343316A1 (enExample)
JP (2) JP2001519401A (enExample)
AT (1) ATE476192T1 (enExample)
AU (1) AU9795898A (enExample)
CY (1) CY1110884T1 (enExample)
DE (1) DE69841806D1 (enExample)
DK (1) DK1023080T3 (enExample)
ES (1) ES2351876T3 (enExample)
PT (1) PT1023080E (enExample)
WO (1) WO1999018987A1 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US7081241B1 (en) * 1998-10-06 2006-07-25 The Trustees Of Columbia University In The City Of New York Extracellular rage binding protein (EN-RAGE) and uses thereof
US6790443B2 (en) * 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US6555651B2 (en) * 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
US7101838B2 (en) * 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
US6465422B1 (en) * 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
AU765719B2 (en) * 1998-10-06 2003-09-25 Trustees Of Columbia University In The City Of New York, The Extracellular novel rage binding protein (EN-RAGE) and uses thereof
WO2001012598A2 (en) * 1999-08-13 2001-02-22 The Trustees Of Columbia University In The City Of New York METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF
US20050170382A1 (en) * 1999-10-06 2005-08-04 The Trustees Of Columbia University In The City Of New York. RAGE-related compositions
US6908741B1 (en) 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE
US6613801B2 (en) 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
EP1724589A3 (en) * 2000-05-30 2007-04-25 TransTech Pharma Inc. Methods to identify compounds that modulate rage
US7423177B2 (en) 2001-03-05 2008-09-09 Transtech Pharma, Inc. Carboxamide derivatives as therapeutic agents
US7919670B1 (en) 2000-08-14 2011-04-05 The Trustees Of Columbia University In The City Of New York Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) in brain and uses thereof
PE20020394A1 (es) 2000-08-18 2002-06-21 Agouron Pharma Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
AU2002213192A1 (en) * 2000-10-13 2002-04-22 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
JP2004523565A (ja) 2001-03-05 2004-08-05 トランス　テック　ファーマ，インコーポレイテッド 治療因子としてのベンゾイミダゾール誘導体
CA2476594C (en) 2002-03-05 2012-10-09 Transtech Pharma, Inc. Mono-and bicyclic azole derivatives that inhibit the interaction of ligands with rage
MXPA05001758A (es) * 2002-08-16 2005-08-19 Wyeth Corp Composiciones y metodos para el tratamiento de trastornos asociados a receptor para productos finales de glicatacion avanzada (rage).
US8067371B2 (en) * 2003-05-09 2011-11-29 The Trustees Of Columbia University In The City Of New York RAGE G82S-related methods and compositions for treating inflammatory disorders
EP1771565B1 (en) * 2004-07-20 2012-09-05 The Feinstein Institute for Medical Research Rage protein derivatives
GEP20105110B (en) * 2004-08-03 2010-11-10 Transtech Pharma Inc Rage fusion proteins and their use
AU2005271449A1 (en) * 2004-08-03 2006-02-16 The Trustees Of Columbia University In The City Of New York RAGE fusion proteins and methods of use
EP1799242A4 (en) * 2004-09-16 2009-11-11 Univ California TYPE G PEPTIDES AND OTHER ACTIVE SUBSTANCES TO REDUCE ATHEROSCLEROSIS AND OTHER DISEASES
CA2581505A1 (en) * 2004-09-27 2006-04-06 Centocor, Inc. Srage mimetibody, compositions, methods and uses
CA2595067A1 (en) 2004-12-06 2006-06-15 The Regents Of The University Of California Methods for improving the structure and function of arterioles
US9291621B2 (en) * 2005-01-18 2016-03-22 AbbVie Deutschland GmbH & Co. KG AGER-peptides and use thereof
WO2006077101A2 (de) * 2005-01-18 2006-07-27 Abbott Gmbh & Co. Kg Ager-peptide und deren verwendung
EP1869464A4 (en) * 2005-03-17 2009-12-02 Univ Columbia RAGE-DIAPHANOUS INTERACTION AND CORRESPONDING COMPOSITIONS AND METHODS
NZ563187A (en) * 2005-04-29 2010-05-28 Univ California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US20080207499A1 (en) * 2005-06-29 2008-08-28 Gaetano Barile Rage-related methods for treating and preventing diabetic retinopathy
ES2431632T3 (es) * 2005-12-23 2013-11-27 Gcoder Systems Ab Patrón de posicionamiento
WO2007094926A2 (en) * 2006-02-09 2007-08-23 Transtech Pharma, Inc. Rage fusion proteins and methods of use
EP2380983A3 (en) 2006-05-05 2012-12-05 TransTech Pharma Inc. RAGE fusion proteins, formulations, and methods of use thereof
US20080199467A1 (en) * 2007-02-15 2008-08-21 Mjalli Adnan M M Immunoglobulin fusion proteins and methods of making
WO2008153957A1 (en) * 2007-06-07 2008-12-18 The Trustees Of Columbia University In The City Of New York Uses of rage antagonists for treating obesity and related diseases
EP2158210B1 (en) 2007-06-14 2015-12-09 Galactica Pharmaceuticals, Inc. Rage fusion proteins
WO2009032693A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
CA2697957A1 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
CA2757079C (en) 2009-04-20 2015-05-19 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
WO2011041198A1 (en) 2009-09-30 2011-04-07 Transtech Pharma, Inc. Substituted imidazole derivatives for treatment of alzheimers disease
TWI510241B (zh) 2010-02-18 2015-12-01 Vtv Therapeutice Llc 苯基－雜芳基衍生物及其使用方法
JP5999542B2 (ja) * 2010-11-18 2016-09-28 国立研究開発法人農業・食品産業技術総合研究機構 リガンド様活性を有する分子の検出方法
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
US9717710B2 (en) 2012-10-05 2017-08-01 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
KR101595630B1 (ko) * 2013-01-18 2016-02-18 성균관대학교산학협력단 Rage 단백질-베타아밀로이드 상호작용 억제제, 및 이를 유효성분으로 함유하는 베타아밀로이드 집적 관련 질환의 예방 또는 치료용 약학적 조성물
BR112017001860A2 (pt) 2014-07-31 2018-02-27 Uab Research Foundation peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
EP3864008A1 (en) 2018-10-10 2021-08-18 vTv Therapeutics LLC Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5585344A (en) 1984-03-19 1996-12-17 The Rockefeller University Liver-derived receptors for advanced glycosylation endproducts and uses thereof
EP0802797A1 (en) 1994-02-03 1997-10-29 The Picower Institute For Medical Research Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US6184205B1 (en) * 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
EP0870040A2 (en) * 1995-12-29 1998-10-14 Chiron Corporation Gene delivery vehicle-targeting ligands
AU1832797A (en) 1996-01-26 1997-08-20 Trustees Of Columbia University In The City Of New York, The A polypeptide from lung extract which binds amyloid-beta peptide
DE69731463T2 (de) * 1996-02-21 2005-10-27 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Rekombinante ribonuklease proteine
US5864018A (en) 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
WO1997039121A1 (en) 1996-04-16 1997-10-23 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
US5688653A (en) 1996-06-27 1997-11-18 The Picower Institute For Medical Research 3-alkylamino-2-hydroxy-4-hydroxymethyl-2-cyclopenten-1-one advanced glycosylation endproducts and methods of use therefor
US6555651B2 (en) * 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof

Also Published As

Publication number Publication date
EP1023080B1 (en) 2010-08-04
US20010053357A1 (en) 2001-12-20
EP1023080A1 (en) 2000-08-02
JP2001519401A (ja) 2001-10-23
DE69841806D1 (de) 2010-09-16
EP2343316A1 (en) 2011-07-13
US6555651B2 (en) 2003-04-29
HK1031100A1 (en) 2001-06-01
PT1023080E (pt) 2010-10-18
CY1110884T1 (el) 2015-06-10
DK1023080T3 (da) 2010-11-15
WO1999018987A1 (en) 1999-04-22
AU9795898A (en) 1999-05-03
ATE476192T1 (de) 2010-08-15
JP2010143932A (ja) 2010-07-01
EP1023080A4 (en) 2003-03-19

Similar Documents

Publication Publication Date Title
ES2351876T3 (es) Sitio de enlazamiento del ligando de rage y usos del mismo.
US7258857B2 (en) Rage-related methods for treating inflammation
JP4976475B2 (ja) 後生的グリケーション最終生成物の可溶性レセプター（ｓＲＡＧＥ）を用いて加速性アテローム性動脈硬化症を予防する方法
EP1121454B1 (en) Extracellular novel rage binding protein (en-rage) and uses thereof
EP0964870B1 (fr) Recepteur lsr, clonage et applications
US20080019986A1 (en) Methods of inhibiting binding of beta-sheet fibril to rage and consequences thereof
US6555340B1 (en) Nucleic acid encoding bovine extracellular rage binding protein (en-rage)
US7404952B2 (en) Protein disulfide isomerase and ABC transporter homologous proteins involved in the regulation of energy homeostasis
HK1031100B (en) Ligand binding site of rage and uses thereof
HK1159660A (en) Ligand binding site of rage and uses thereof
CA2306991A1 (en) Ligand binding site of rage and uses thereof
JP3640254B2 (ja) 間質性肺炎治療薬
HK1110875A (en) Extracellular novel rage binding protein (en-rage) and uses thereof
MXPA00001275A (en) METHOD TO PREVENT ACCELERATED ATHEROSCLEROSIS USING (sRAGE) SOLUBLE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS
EP0527774A1 (en) Calcitonin gene related peptide for the treatment of undescended testicles